Compare IPCA Labs with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PANACEA BIOTECH - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PANACEA BIOTECH IPCA LABS/
PANACEA BIOTECH
 
P/E (TTM) x 23.0 11.3 204.2% View Chart
P/BV x 4.4 2.4 184.6% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 IPCA LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-19
PANACEA BIOTECH
Mar-19
IPCA LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,042354 294.7%   
Low Rs590138 427.0%   
Sales per share (Unadj.) Rs298.674.6 400.5%  
Earnings per share (Unadj.) Rs35.06.7 524.0%  
Cash flow per share (Unadj.) Rs49.415.5 319.0%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.157.2 432.0%  
Shares outstanding (eoy) m126.3561.25 206.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.73.3 82.9%   
Avg P/E ratio x23.336.8 63.3%  
P/CF ratio (eoy) x16.515.9 104.0%  
Price / Book Value ratio x3.34.3 76.8%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,10815,061 684.6%   
No. of employees `00013.42.3 580.9%   
Total wages/salary Rs m7,8741,471 535.4%   
Avg. sales/employee Rs Th2,807.01,973.6 142.2%   
Avg. wages/employee Rs Th585.8635.6 92.2%   
Avg. net profit/employee Rs Th329.0176.8 186.1%   
INCOME DATA
Net Sales Rs m37,7324,567 826.2%  
Other income Rs m57745 1,287.5%   
Total revenues Rs m38,3094,612 830.7%   
Gross profit Rs m6,9012,030 340.0%  
Depreciation Rs m1,824540 337.8%   
Interest Rs m1891,048 18.0%   
Profit before tax Rs m5,465486 1,123.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,04277 1,352.0%   
Profit after tax Rs m4,422409 1,081.0%  
Gross profit margin %18.344.4 41.2%  
Effective tax rate %19.115.9 120.3%   
Net profit margin %11.79.0 130.8%  
BALANCE SHEET DATA
Current assets Rs m23,7782,415 984.8%   
Current liabilities Rs m10,9759,077 120.9%   
Net working cap to sales %33.9-145.9 -23.3%  
Current ratio x2.20.3 814.5%  
Inventory Days Days10465 159.4%  
Debtors Days Days6671 93.0%  
Net fixed assets Rs m20,3688,333 244.4%   
Share capital Rs m25361 412.2%   
"Free" reserves Rs m30,9713,443 899.6%   
Net worth Rs m31,2243,504 891.1%   
Long term debt Rs m1,409461 305.4%   
Total assets Rs m45,50713,755 330.8%  
Interest coverage x30.01.5 2,046.7%   
Debt to equity ratio x00.1 34.3%  
Sales to assets ratio x0.80.3 249.7%   
Return on assets %10.110.6 95.6%  
Return on equity %14.211.7 121.3%  
Return on capital %17.338.7 44.8%  
Exports to sales %45.920.9 219.6%   
Imports to sales %16.68.1 203.9%   
Exports (fob) Rs m17,308954 1,814.5%   
Imports (cif) Rs m6,266372 1,684.9%   
Fx inflow Rs m17,3081,203 1,438.7%   
Fx outflow Rs m6,266467 1,342.8%   
Net fx Rs m11,042736 1,499.5%   
CASH FLOW
From Operations Rs m4,9231,049 469.4%  
From Investments Rs m-1,563-54 2,921.7%  
From Financial Activity Rs m-1,832-1,011 181.1%  
Net Cashflow Rs m1,528-20 -7,754.8%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.6 1,900.0%  
FIIs % 25.3 1.3 1,946.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.6 73.7%  
Shareholders   36,892 10,259 359.6%  
Pledged promoter(s) holding % 2.1 35.1 6.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  WYETH LTD  CADILA HEALTHCARE  ALEMBIC LTD  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 11, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - TORRENT PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS